Discovering small molecule drugs that create neoantigens
Our approach targets the dynamics of cancer neoantigen evolution through the discovery and design of effective, well-tolerated medicines that will become a key part of the next-generation of cancer immunotherapies.
Our vision
Our medicines will stimulate immunity directly at cancer’s core
Clinicians commonly observe robust and sustained immune responses against certain cancers that lack the DNA mismatch repair ('MMR') genes targeted by our approach.
Discovery our technology
